NC

Nilkesh Champalal Oswal

Active Director Director DIN 09040821
DIN 09040821 First appointment Jan 2021 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jan 2021
Shareholding value β€’β€’β€’β€’ Premium profile

About Nilkesh Champalal Oswal

Data last updated:

Nilkesh Champalal Oswal is a Director at Mangalmurti Pharma Private Limited (since 2021). The company operates in Chemicals.

DIN 09040821
Primary Designation Director
Industry Chemicals
First Appointment 23 Jan 2021
Oldest Company Age 5 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Mangalmurti Pharma Private Limited U24299PN2021PTC197996
Director23 Jan 20212021Active

Board colleagues of Nilkesh Champalal Oswal

Directorship timeline

Open interactive timeline →
Mangalmurti Pharma Private Limited
Premium access

Shareholding and investment profile for Nilkesh Champalal Oswal

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nilkesh Champalal Oswal

Nilkesh Champalal Oswal currently holds 1 directorship: Mangalmurti Pharma Private Limited (Director, since 23 Jan 2021).

Nilkesh Champalal Oswal was first appointed on 23 Jan 2021 as Director at Mangalmurti Pharma Private Limited.

The current boards of Nilkesh Champalal Oswal's companies include Pradeep Rajaram Pawar (Mangalmurti Pharma Private Limited), Sachin Bajrang Pawar (Mangalmurti Pharma Private Limited), Tejaswi Pradipkumar Pawar (Mangalmurti Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available